(firstQuint)This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-nave Nonmetastatic Prostate Cancer.

.

 The objective of this study is to evaluate the tolerability and safety of TAK-385 in patients with androgen deprivation treatment-naive non-metastatic prostate cancer.

 This study consists of two parts: Part A, multiple dose-rising phase and Part B, an expansion phase.

.

 This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-nave Nonmetastatic Prostate Cancer.

@highlight

To evaluate the tolerability and safety of TAK-385 in patients with androgen deprivation treatment-naive non-metastatic prostate cancer